OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Saturday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Down 14.2 %

NASDAQ:OPGN opened at $0.89 on Friday. The firm’s 50 day moving average is $1.03 and its 200 day moving average is $1.50. OpGen has a 12 month low of $0.53 and a 12 month high of $9.90.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.